Mead Johnson (MJN) gains 5.3% premarket following earlier news that testing on its Enfamil formula showed that it's safe.
Mead Johnson performed tests on its Enfamil baby formula, and said it was unable to find any of the bacteria linked to the death of a child last week. The company expressed confidence that its product is safe. MJN rose 6 percent before the bell.
Mead Johnson Nutrition Co. (MJN) said tests it conducted on samples of its Enfamil baby formula tied to a U.S. Food and Drug Administration probe found no presence of bacteria. The company called the product safe.
Two babies tested positive this month for the environmental bacteria Cronobacter, including a newborn in Lebanon, Missouri, who died. The samples tested by Mead Johnson matched those being screened by government regulators and, using their methods, found no Cronobacter, the company said in a statement yesterday.
Mead Johnson performed tests on its Enfamil baby formula, and said it was unable to find any of the bacteria linked to the death of a child last week. The company expressed confidence that its product is safe. MJN rose 6 percent before the bell.
Mead Johnson Nutrition Co. (MJN) said tests it conducted on samples of its Enfamil baby formula tied to a U.S. Food and Drug Administration probe found no presence of bacteria. The company called the product safe.
Two babies tested positive this month for the environmental bacteria Cronobacter, including a newborn in Lebanon, Missouri, who died. The samples tested by Mead Johnson matched those being screened by government regulators and, using their methods, found no Cronobacter, the company said in a statement yesterday.
For the latest updates on the stock market, visit,
http://daytradingstock-blog.blogspot.com/
